Clinical trial
Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants
NCT00438230 · Azienda Ospedaliera Universitaria Policlinico, Other · Completed
Key facts
| NCT number | NCT00438230 |
|---|---|
| Title | Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants |
| Official title | Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs |
| Acronym | DACUS |
| Lead sponsor | Azienda Ospedaliera Universitaria Policlinico, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Deep Vein Thrombosis |
| Intervention type | Drug |
| Interventions | Warfarin |
| Enrollment | 250 |
| Start date | Nov 1, 2003 |
| Completion | Sep 1, 2006 |
| First posted | Feb 22, 2007 |
| Last update posted | Feb 22, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: